<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Anti-COVID-19 (anticoronaviral-2) activities (along with human/mammalian cells toxicities) of 
   <bold>CoViTris2020</bold> and 
   <bold>ChloViD2020</bold> (using remdesivir, ivermectin, and favipiravir, respectively, as the reference drugs) against SARS-CoV-2 in Vero E6 cells
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" rowspan="2">Classification</th>
    <th align="left" rowspan="2">Compound Name</th>
    <th align="left" rowspan="2">CC
     <sub>50</sub>
     <sup>a</sup>
     <break/>(μM)
    </th>
    <th align="left" colspan="3">Inhibition of SARS-CoV-2 in vitro (μM)</th>
   </tr>
   <tr>
    <th align="left">100% CPE Inhibitory concentration (CPEIC
     <sub>100</sub>)
     <sup>b</sup>
    </th>
    <th align="left">50% Reduction in infectious virus (EC
     <sub>50</sub>)
     <sup>c</sup>
    </th>
    <th align="left">50% Reduction in viral RNA copy (EC
     <sub>50</sub>)
     <sup>d</sup>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="2">Target compounds</td>
    <td align="left">
     <bold>CoViTris2020</bold>
    </td>
    <td align="left">&gt; 100</td>
    <td char="." align="char">0.99 ± 0.11</td>
    <td char="." align="char">0.31 ± 0.02</td>
    <td align="left">0.33 ± 0.02</td>
   </tr>
   <tr>
    <td align="left">
     <bold>ChloViD2020</bold>
    </td>
    <td align="left">&gt; 100</td>
    <td char="." align="char">1.97 ± 0.23</td>
    <td char="." align="char">1.01 ± 0.07</td>
    <td align="left">1.23 ± 0.09</td>
   </tr>
   <tr>
    <td align="left" rowspan="3">Reference compounds</td>
    <td align="left">
     <bold>Remdesivir</bold>
    </td>
    <td align="left">&gt; 100</td>
    <td char="." align="char">22.50 ± 3.02</td>
    <td char="." align="char">20.17 ± 1.72</td>
    <td align="left">23.88 ± 1.96</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Ivermectin</bold>
    </td>
    <td align="left">&gt; 100</td>
    <td char="." align="char">83.05 ± 7.15</td>
    <td char="." align="char">53.00 ± 3.99</td>
    <td align="left">62.44 ± 5.08</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Favipiravir</bold>
    </td>
    <td align="left">&gt; 100</td>
    <td char="." align="char">98.82 ± 8.64</td>
    <td char="." align="char">94.09 ± 6.79</td>
    <td align="left">&gt; 100</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <sup>a</sup>CC
   <sub>50</sub> or 50% cytotoxic concentration is the concentration of the tested compound that kills half the cells in an uninfected cell culture. CC
   <sub>50</sub> was determined with serially diluted compounds in Vero E6 cells at 48 h postincubation using CellTiter-Glow Luminescent Cell Viability Assay (Promega)
  </p>
  <p>
   <sup>b</sup>CPEIC
   <sub>100</sub> or 100% CPE inhibitory concentration is the lowest concentration of the tested compound that causes 100% inhibition of the cytopathic effects (CPE) of SARS-CoV-2 virus in Vero E6 cells under increasing concentrations of the tested compound at 48 h postinfection. Compounds were serially twofold or fourfold diluted from 100 μM concentration
  </p>
  <p>
   <sup>c</sup>EC
   <sub>50</sub> or 50% effective concentration is the concentration of the tested compound that is required for 50% reduction in infectious SARS-CoV-2 virus particles in vitro. EC
   <sub>50</sub> is determined by infectious virus yield in culture supernatant at 48 h postinfection (log
   <sub>10</sub> TCID
   <sub>50</sub>/mL)
  </p>
  <p>
   <sup>d</sup>EC
   <sub>50</sub> or 50% effective concentration is the concentration of the tested compound that is required for 50% reduction in SARS-CoV-2 viral RNA copies in vitro. EC
   <sub>50</sub> is determined by viral RNA copies number in culture supernatant at 48 h postinfection (log
   <sub>10</sub> RNA copies/mL)
  </p>
 </table-wrap-foot>
</table-wrap>
